Karen Bell

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease”.

Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

Alzheimer s Research & Therapy(2025)10.1186/s13195-025-01745-3

N/A

0.256DataRank · unranked

4 citations

Diane M. Jacobs, Karen Messer, David P. Salmon, Cheryl L. Wellington, Sophie Stukas +61 more

Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study

The Lancet Neurology(2024)10.1016/s1474-4422(24)00426-5

N/A

0DataRank · unranked

27 citations

Matthew Zammit, Jiebiao Wang, Benjamin L. Handen, Tobey J. Betthauser, Charles M. Laymon +71 more

The effects of mosaicism on biological and clinical markers of Alzheimer's disease in adults with Down syndrome

EBioMedicine(2024)10.1016/j.ebiom.2024.105433

N/A

0DataRank · unranked

6 citations

Lam‐Ha T. Dang, Alice Lee, Sharon J. Krinsky‐McHale, Deborah Pang, Lisa Melilli +72 more